N-乙基-4-溴苯磺酰胺 | 1984-25-4

• 物质功能分类: 原料药 - 人工合成抗感染类药 - 磺胺类药及增效剂
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-乙基-4-溴苯磺酰胺
• 中文别名: 4-溴-N-乙基苯磺酰胺
• 英文名称: 4-bromo-N-ethylbenzenesulfonamide
• CAS: 1984-25-4
• 化学式: C₈H₁₀BrNO₂S
• mdl: MFCD01215100
• 分子量: 264.143
• InChiKey: CEPUEFFXFOOTDZ-UHFFFAOYSA-N

物化性质

• 熔点：
  69-71
• 沸点：
  342.5±44.0 °C(Predicted)
• 密度：
  1.529±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  54.6
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2935009090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
N-Ethyl 4-bromobenzenesulfonamide
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
N-Ethyl 4-bromobenzenesulfonamide
Ingredient name:
CAS number: 1984-25-4

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H10BrNO2S
Molecular weight: 264.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-乙基-4-溴苯磺酰胺 在 tetrakis(actonitrile)copper(I) hexafluorophosphate 、 2,2'-联喹啉 、 potassium carbonate 作用下， 以 乙腈 为溶剂， 反应 8.0h， 生成
  参考文献：
  名称：

  铜催化的三氟甲基化和芳族磺酰基基团链烯烃的环化反应，用于构建1,2-苯并噻嗪烷二氧化物类化合物。

  摘要：

  多才多艺的系统：已开发出一种有效的铜催化串联的三氟甲基化/电子缺陷型芳香环的环。该方法提供了一种在温和的条件下合成三氟甲基化的1,2-苯并噻嗪烷二氧化物的强大而直接的方法（请参见方案）。通过一系列动力学实验和同位素标记研究研究了该机制。

  DOI：

  10.1002/chem.201303623
• 作为产物：
  描述：

  乙胺盐酸盐 、 4-溴苯磺酰氯 在 potassium hydroxide 作用下， 以 二氯甲烷 、 水 为溶剂， 生成 N-乙基-4-溴苯磺酰胺
  参考文献：
  名称：

  新型姜黄素衍生物作为P-糖蛋白抑制剂：多药耐药细胞对阿霉素的分子建模，合成和敏化。

  摘要：

  数十年来，人们一直在研究MDR1 / P-糖蛋白（Pgp）/ ABCB1多药转运体作为抗肿瘤治疗的药物靶点。已知天然产物姜黄素为能够阻断Pgp介导的外排和使多药耐药（MDR）细胞对Pgp转运的药物阿霉素（Dox）敏感的化合物提供了有效的支架。我们进行了分子动力学模拟，并将姜黄素衍生物对接到Pgp模型中。基于这些计算，提出了一系列具有预测的代谢稳定性和/或改善的结合亲和力的吡唑并姜黄素衍生物，用于合成和评估针对Dox选择的K562 / 4亚型（K562人慢性粒细胞性白血病细胞系的衍生物）的MDR逆转能力。化合物16和19都是带有Np-苯基羧酸酰胺取代基的二甲基姜黄素吡唑衍生物，是通过细胞内Dox积累确定的最有效的Pgp阻滞剂。此外，在无毒的亚微摩尔浓度16和19可使K562 / 4细胞对Dox显着敏感。这些结果与16和19的良好水溶性一起，表明姜黄素的新型吡唑并衍生物是开发临床适用的Pgp拮抗剂的有前途的支架。

  DOI：

  10.1016/j.ejmech.2020.112331

文献信息

• [EN] PROTEIN KINASE MKK4 INHIBITORS FOR PROMOTING LIVER REGENERATION OR REDUCING OR PREVENTING HEPATOCYTE DEATH<br/>[FR] INHIBITEURS DE PROTÉINE KINASE MKK4 POUR FAVORISER LA RÉGÉNÉRATION HÉPATIQUE OU POUR RÉDUIRE OU PRÉVENIR LA MORT DES HÉPATOCYTES
  申请人：HEPAREGENIX GMBH

  公开号：WO2019149738A1

  公开（公告）日：2019-08-08

  The invention relates to pyrazolo-pyridine compounds which inhibit mitogen-activated protein kinase kinase 4 (MKK4) and in particular, selectively inhibit MKK4 over protein kinases JNK1 and MKK7. The compounds are useful for promoting liver regeneration or reducing or preventing hepatocyte death. They are further useful for treating osteoarthritis or rheumatoid arthritis, or CNS-related diseases.

  这项发明涉及抑制有丝分裂原活化蛋白激酶激酶4（MKK4）的吡唑啉-吡啶化合物，特别是选择性地抑制MKK4而不影响蛋白激酶JNK1和MKK7。这些化合物可用于促进肝再生或减少或预防肝细胞死亡。它们还可用于治疗骨关节炎或类风湿性关节炎，或中枢神经系统相关疾病。
• [EN] TRICYCLIC ALKYNES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN<br/>[FR] ALCYNES TRICYCLIQUES QUI INTERAGISSENT AVEC LA PROTÉINE RÉGULATRICE DE GLUCOKINASE
  申请人：AMGEN INC

  公开号：WO2014035872A1

  公开（公告）日：2014-03-06

  The present invention relates to tricyclic alkyne compounds of formula I that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.

  本发明涉及与葡萄糖激酶调节蛋白相互作用的式I的三环炔化合物。此外，本发明涉及使用这些化合物或其药学上可接受的盐治疗2型糖尿病和其他涉及葡萄糖激酶调节蛋白的疾病和/或症状的方法，以及含有这些化合物或其药学上可接受的盐的药物组合物。
• Design and synthesis of 1H-pyrazolo[3,4-b]pyridines targeting mitogen-activated protein kinase kinase 4 (MKK4) - A promising target for liver regeneration
  作者：Bent Pfaffenrot、Philip Klövekorn、Michael Juchum、Roland Selig、Wolfgang Albrecht、Lars Zender、Stefan A. Laufer

  DOI：10.1016/j.ejmech.2021.113371

  日期：2021.6

  vemurafenib (8), that showed a high off-target affinity to MKK4 in an initial screening, we followed a scaffold-hopping approach, changing the core heterocycle from 1H-pyrrolo[2,3-b]pyridine to 1H-pyrazolo[2,3-b]pyridine (10). Affinity to MKK4 could be conserved while the selectivity against off-target protein kinases was slightly improved. Further modifications led to 58 and 59 showing high affinity

  目前，治疗肝功能衰竭的治疗选择非常有限。由于最近通过体内RNAi 实验发现丝裂原活化蛋白激酶激酶 4 (MKK4)是肝细胞再生的主要调节因子，因此我们致力于开发一种针对该蛋白激酶的小分子。从已获批的 BRAF V600E抑制剂 vemurafenib ( 8 )开始，该抑制剂在初始筛选中显示出对 MKK4 的高脱靶亲和力，我们采用了支架跳跃方法，将核心杂环从 1 H -吡咯 [2,3- b ]吡啶到 1 H-吡唑并[2,3- b ]吡啶（10）。对 MKK4 的亲和力可以得到保留，而对脱靶蛋白激酶的选择性略有提高。进一步的修改导致58和59在低纳摩尔范围内显示出对 MKK4 的高亲和力，以及来自必需抗靶点（MKK7、JNK1）和脱靶点（BRAF、MAP4K5、ZAK）的强制性多参数优化的优异选择性。 MKK4 通路。在此我们报告了此类中的第一个选择性 MKK4 抑制剂。
• Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use
  申请人：JAEHNE Gerhard

  公开号：US20090215728A1

  公开（公告）日：2009-08-27

  This invention relates to arylaminoaryl-alkyl-substituted imidazolidone-2,4-diones of formula (I) and also to their physiologically tolerated salts: Wherein R, R′, R1 to R10, A, D, E, G, L and p are as defined herein. The invention also relates to processes for preparing them, pharmaceutical compositions comprising them and their therapeutic use. The compounds are suitable, for example, as anti-obesity drugs and for treating cardiometabolic syndrome.

  这项发明涉及公式（I）中的芳基氨基芳基烷基取代的咪唑烷二酮及其生理耐受的盐： 其中R、R'、R1至R10、A、D、E、G、L和p如本文所定义。该发明还涉及制备它们的方法、包含它们的药物组合物以及它们的治疗用途。这些化合物适用于例如作为抗肥胖药物和治疗心脏代谢综合征。
• Manganese-Catalyzed N–F Bond Activation for Hydroamination and Carboamination of Alkenes
  作者：Yun-Xing Ji、Jinxia Li、Chun-Min Li、Shuanglin Qu、Bo Zhang

  DOI：10.1021/acs.orglett.0c03916

  日期：2021.1.1

  the precatalyst and a cheap silane, (MeO)3SiH, as both the hydrogen-atom donor and the F-atom acceptor, enabling intramolecular/intermolecular hydroaminations of alkenes, two-component carboamination of alkenes, and even three-component carboamination of alkenes. A wide range of valuable aliphatic sulfonamides can be readily prepared using these practical reactions.

  据报道，可见光促进了通过锰催化的NF键活化策略从N-氟磺酰胺中生成酰胺基的方法。该方案采用简单的锰络合物Mn 2（CO）10作为预催化剂，使用廉价的硅烷（MeO）3 SiH作为氢原子供体和F原子受体，从而实现烯烃的分子内/分子间加氢胺化，烯烃的两组分碳氨化，甚至烯烃的三组分碳氨化。使用这些实际反应可以很容易地制备出多种有价值的脂族磺酰胺。